MeSH D000172 - acromegaly
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Octreotide | Octreotide | 2011-02-10 | |||
| Cipla | Lanreotide | Lanreotide | 2021-12-17 | |||
| Novartis | Octreotide | Sandostatin | 1988-10-21 | $1,249 M | Q2/23-Q2/26 | |
| Pfizer | Pegvisomant | Somavert | 2002-11-12 | $267 M | Y2023 | |
| Sun Pharmaceutical Industries | Octreotide | Octreotide | 2008-03-04 | |||
| Wockhardt | Octreotide | Octreotide | 2011-05-11 | |||
| Chiesi Farmaceutici | Octreotide | Mycapssa | 2029-09-17 | 2020-06-26 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
50%3/6
Phase 2
50%4/8
Phase 3
91%10/11
Approved: 6Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use